News

U.S. Department of Defense Selects Kaléo to Develop Next Generation Nerve Agent Countermeasure

Kaléo, a privately-held U.S. pharmaceutical company, today announced their selection by the U.S. Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) to develop a reconstitution auto-injector device that delivers atropine, the Reconstitution Auto-Injector Device – Atropine (RAD-A). This will be the first of a new generation of medical countermeasures utilizing an innovative reconstitution technology and is expected to significantly extend the shelf life of the drug as well as its stability under extreme conditions. The reconstitution development contract is valued at more than $39 million over the next five years.

“The goal for this project is to produce an auto-injector device capable of automatically reconstituting a range of military countermeasures,” said Colonel Matthew G. Clark, Joint Project Manager for JPM CBRN Medical. “This is an exciting new addition to the suite of auto-injector products that enable a layered defense against CBRN threats for the Warfighter.”

Unlike the currently fielded atropine autoinjectors, the RAD-A will maintain the atropine in a dry format until the drug is automatically reconstituted into a liquid immediately prior to administration. Atropine sulfate injection is used for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides. The DOD intends the RAD-A to be an important addition to the auto-injector products that constitute a layered defense against CBRN threats for military personnel and potentially civilian stockpiles.

“Kaléo’s platform technology is well suited to handle the next generation of medical countermeasures that require wet/dry formulations, large volumes, high viscosity, the simultaneous delivery of multiple drugs, or other needs to support the Joint Force and our allies.” said Mark A. Herzog, Kaléo’s vice president, global corporate affairs, defense and homeland security.

The Other Transaction Agreement for the RAD-A prototype was awarded through the Army Contracting Command Aberdeen Proving Ground (ACC-APG), Edgewood Division, on behalf of the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) in collaboration with the Chemical and Biological Defense Program (CBDP). The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the Nation’s CBRN response capability.

RAD-A is the second DOD contract awarded to Kaléo. In 2019, the company was selected by JPM CBRN Medical to develop the Naloxone Auto-injector 10 mg Rapid Opioid Countermeasure System (ROCS), which was delivered under budget, six months ahead of schedule, and approved by the U.S. Food and Drug Administration (FDA) in 2022. The JPM CBRN Medical Rapid Opioid Countermeasure System (ROCS) product team was selected to receive the 2022 MHSRS award for Outstanding Program Management in recognition of the team’s ability to minimize the ROCS program’s developmental risks, manage costs, schedule, and performance, and adhere to all applicable regulatory requirements.

 

Learn more here.

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep